Response Genetics Regains Nasdaq Compliance | GenomeWeb

NEW YORK (GenomeWeb News) – Response Genetics said on Monday that it has regained compliance with a Nasdaq requirement calling for a minimum $35 million market value of listed securities.

The Los Angeles-based diagnostics firm said that Nasdaq notified it that it regained compliance on Oct. 5 and the delisting matter is now closed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.